Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
BACKGROUND: Alemtuzumab (MabCampath or Campath; Genzyme, Cambridge, MA) is a CD52-specific monoclonal antibody that causes profound and sustained lymphocyte depletion. Its use as an induction therapy in organ transplantation is increasing. Since our last systematic review in 2006, where we identifi...
| Auteurs principaux: | , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2012
|